Technology 108 of 266
Immunotherapy
5 EIC Accelerator winners build on Immunotherapy, 0% of the classified companies, in 1 sector and 1 industry.
5
Companies
1
Sectors
1
Industries
4
Countries
0%
Exits
20%
Show signs of scaling
Sectors
- Health5 (100%)
Industries
Companies per year of first award
2019
2020
2021
2022
2023
2024
- Immunotherapy
Show the numbers
| Companies | Immunotherapy | |
|---|---|---|
| 2019 | 1 | 1 |
| 2020 | 1 | 1 |
| 2021 | 2 | 2 |
| 2022 | 0 | 0 |
| 2023 | 1 | 1 |
| 2024 | 0 | 0 |
What happened to them (5 of 5 checked)
- Active4 (80%)
- Exit0 (0%)
- Failed1 (20%)
- Other0 (0%)
Signs of scaling
- Scaling1 (20%)
- Not scaling3 (60%)
- Scaling unclear1 (20%)
Countries
Keywords
- Autoimmune disease
- Clever-1
- Coeliac disease
- Cold tumours
- Glaucoma
- Immuno-oncology
- Immunomodulation
- Inflammation
- Innate lymphoid cells
- Kidney disease
- Macrophages
- Metabolic diseases
- Mucosal patches
- Myelodysplastic syndrome
- Neuroimmunology
- Oncology
- Ophthalmology
- Oral immune tolerance
- Osteosarcoma
- Sarcoma
- Steroid alternatives
- Uveitis
All 5 companies using Immunotherapy
| Company | Project | Industry | Country | Cut-off | Funding | Status | Rasph |
|---|---|---|---|---|---|---|---|
| HEPHAISTOS-PHARMA | IVI-BoostIntraVenous Immune Boost | Biopharmaceuticals | France | June 2023 | Blended finance | Active | Deep dive |
| Allero Therapeutics BV | SOMIT-CDNovel First-in-Class Specific Oromucosal Immunotherapy (SOMIT) to treat Celiac Disease (CD) | Biopharmaceuticals | Netherlands | October 2021 | Grant first | Active | Deep dive |
| LiMM Therapeutics SA | PILCKYHarnessing the therapeutic Potential of Innate Lymphoid Cells to prevent and treat KidneY-related diseases | Biopharmaceuticals | France | October 2021 | Blended finance | Closed | Deep dive |
| Faron Pharmaceuticals Oy | MAGIFFaron leading the way in macrophage guided immunotherapy | Biopharmaceuticals | Finland | March 2020 | Grant only | Active | Deep dive |
| Tarsier Pharma Ltd | TRSA paradigm change in the treatment of blinding ocular diseases | Biopharmaceuticals | Israel | June 2019 | Grant only | Active | Deep dive |